Non-specific activation of human eosinophil functional responses by vasoactive intestinal peptide  by El-Shazly, Amr et al.
ABSTRACT
Eosinophils and neuropeptides are thought to play
effector roles in allergic diseases, such as rhinitis;
however, little is known about the biological effects of
neuromediators, especially vasoactive intestinal peptide 
(VIP), on eosinophil functional responses. In the present
study, it is shown that VIP induces eosinophil chemotaxis
and eosinophil-derived neurotoxin (EDN) release in
potency comparable with that induced by platelet acti-
vator factor, and in a novel synergistic manner with
recombinant human interleukin-5. Contrary to chemo-
taxis, EDN release was sensitive to staurosporine, the
protein kinase C inhibitor, as well as intracellular
calcium chelation. However, eosinophil treatment with
inhibitors of tyrosine kinases (herbimycin A) and phos-
phatases (pervanadate) resulted in a dose-dependent
potentiation and blockage of VIP-induced eosinophil
chemotaxis, respectively. Treatment of eosinophils with
VIP receptor antagonist did not modify VIP-induced
chemotaxis or EDN release. Furthermore, exploration
of vasoactive intestinal peptide receptor I expression
was lacking in human eosinophils, but not lymphocytes.
These results demonstrate two different mechanisms in
triggering eosinophil activation of functional responses
by VIP, a calcium-dependent degranulation and a
calcium-independent chemotaxis, and elaborate on 
a novel cytokine–neuropeptide interaction in eosin-
ophilic inflammation.
Key words: allergic inflammation, eosinophil, func-
tional response, signal transduction, vasoactive
intestinal peptide.
INTRODUCTION
Eosinophils contain four predominant cationic molecules,
including the eosinophil peroxidase (EPO), the major
basic protein (MBP), the eosinophil cationic protein (ECP),
and the eosinophil-derived neurotoxin (EDN). Eosinophil
accumulation and the release of their granule protein
contents in response to the proper mediators is a crucial
factor in the pathophysiology of allergic inflammation.1–3
In the past decade or so, intensive research in the 
fields of neuropeptides and immune cells has resulted in
accumulating evidence that supports the existence of a
neuroimmune axis.4–6 However, the biological effects of
vasoactive intestinal peptide (VIP) on human eosinophil
are not fully characterized and it is not clear whether VIP
possesses an anti-inflammatory or deleterious effect in
hypersensitivity reactions.7,8
The 28 amino acid VIP polypeptide, which exists in 
the parasympathetic nerves and to a lesser extent in the
sensory fibers, is one of the most abundant of the neuro-
peptides found in the upper and lower airways9,10 and
has been detected in the fluids of hypersensitivity re-
actions.11 The biological effects of VIP on airway functions
include regulation of vascular tone, airway caliber and
mucus secretion.12–15 In addition to its direct physiologic
effects on target tissues, VIP also has the potential to mod-
ulate T lymphocyte functions.16,17 Although VIP affects 
T lymphocytes through its specific receptor, its effects on
other immune and inflammatory cells is still obscure and
there have not been any detailed reports of its effect on
eosinophil chemotaxis or exocytosis.
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Hemopoietic cytokines, such as IL-5, are known for
being specific for human eosinophil differentiation and
for prolonging cell survival in culture, and possess a
strong priming effect on eosinophils, preparing the cell
for an exaggerated inflammatory response to other
inflammatory mediators.18,19 Nonetheless, little is known
about cytokine–neuropeptide interactions in eosinophilic
inflammation.
In the present study, we investigated the effects of VIP, in
the absence or presence of interleukin (IL)-5, on human
eosinophil chemotaxis and degranulation. Release of
EDN was chosen as a degranulating marker for its rela-
tively easy induction in vitro. Results are discussed in
relation to the possible molecular pathway(s) involved.
METHODS
Reagents
Percoll solution and EDN radioimmunoassay (RIA) kits
were purchased from Pharmacia (Uppsala, Sweden). 
NP-40 was from Iwai Kagaku Co., Ltd. (Tokyo, Japan).
CD16 microbeads were from Miltenyi Biotec (Bergisch
Gladbach, Germany). Cytochalasin B and VIP were from
Sigma Chemical Co. (St Louis, MO, USA). The VIP recep-
tor antagonist was from Peninsula Laboratories, Inc.
Herbimycin A, staurosporine, BAPTA-AM and sodium
orthovanadate were from Wako Pure Chemical Industries
(Osaka, Japan). Recombinant human (rh)IL-5 was from
Genzyme Corporation Chemicals (Cambridge, UK).
Cell preparation
Eosinophils and lymphocytes from healthy volunteers
were purified from venous blood anticoagulated with
heparin by Percoll discontinuous gradient centrifugation
followed by negative selection with CD16 immuno-
magnetic beads for high purification of eosinophils, as
described elsewhere.20 Briefly, blood was sedimented
with 6% dextran and the buffy coat was collected and
washed twice with Hank’s balanced salt solution (HBSS)
containing 2% fetal calf serum (FCS) and cells were
overlaid on a discontinuous Percoll gradient of 78%,
71% and 56% Percoll solution in 15 mL polystrene
tubes. The tubes were then centrifuged at 400 g at 20°C
for 30 min, resulting in the formation of three bands and
a pellet. The pellet and the lowest band granulocytes
were collected and sedimented red blood cells were
removed by hypodense lysis. These lymphocyte- and
monocyte-free granulocytes were incubated with CD16
immunomagnetic beads for 30 min at 6–12°C. CD16
is expressed on neutrophils, but not on normal resting
eosinophils. Cells were applied to the top of a pre-
washed column MACS separator (Miltenyi Biotec). The
CD16 negative cells were collected as 98% pure
eosinophilic granulocytes as judged by Hinkelmann
staining. Eosinophils showed a viability greater than
97%, which was confirmed by trypan blue dye exclu-
sion. As for lymphocytes, cells were recovered from the
upper band.
Chemotaxis assay
Chemotactic experiments were performed in 48-well
microchemotaxis chambers as described precisely by
us elsewhere.21 Results of the chemotaxis experiments
were expressed as eosinophils/five selected high power
fields (5 h.p.f.).
Eosinophil degranulation and assay of EDN
concentration
Eosinophil degranulation was induced by VIP or PAF
using 96-well flat-bottom culture plates. Freshly purified
eosinophils were washed twice in RPMI-1640 containing
10% FCS and were resuspended in the same culture
medium at 5 · 105 cells/mL. During preliminary studies,
eosinophils adhering to culture plates released large
amounts of EDN spontaneously, probably due to non-
specific activation, which was inhibited by the addition of
5 m g/mL cytochalasin B to the assay system. Aliquots of
cell suspension (100 m L) were added onto the culture
plate and degranulation was initiated by adding 100 m L
VIP or PAF diluted in the same culture medium as
eosinophil and adjusted to the desired concentrations.
After 1 h incubation at 37°C and 5% CO2, supernatants
from wells were collected carefully and stored at – 20°C
until assayed. Concentrations of EDN in the supernatants
were analyzed by RIA using EDN RIA kits (Pharmacia).
The total content of EDN was measured by lysing
eosinophils with 1% Nonidet P-40.
Priming experiments with rhIL-5
Eosinophils were incubated with 1 ng/mL rhIL-5 for 
30 min at 37°C. After this, cells were washed twice and
resuspended in the culture medium and their chemotaxis
and EDN degranulation by VIP were performed in the
same way as described earlier.
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Ca2+-depleted eosinophils
Ca2+-depleted eosinophils were obtained by incubating
107 cells/mL with 30 m mol/L of the calcium chelating
agent BAPTA-AM in test medium (130 mmol/L NaCl, 
5 mmol/L NaHCO3, 4.6 mmol/L KCl, 5 mmol/L glucose,
2 mmol/L ethyleneglycol-bis(b -aminoethyl ether)-N,N,
N¢ ,N¢ -tetraacetic acid (EGTA) and 20 mmol/L N-2-
hydroxyethylpiperazine-N¢ -2-ethanesulfonic acid (HEPES),
for 30 min at 37°C.
Total RNA extraction and cDNA synthesis
Total cellular RNA of eosinophils and lymphocytes was
extracted using the guanidium isothiocynate method; 
1 m L total cellular RNA, 1 m L (500 ng) Oligo(dt) 12–18
primer supplied in diethyl pyrocarbonate (DEPC)-treated
water and 3 m L sterile distilled water were heated to
70°C for 10 min followed by quick chilling on ice and
were made up to a total volume of 19.3 m L containing
first strand buffer, 10 mmol/L deoxyribonucleoside
triphosphates (dNTP), 0.1 mol/L dithiothreitol (DTT),
and superscript reverse transcriptase (GIBCO BRL). The
samples were incubated for 10 min at 37°C and then 
50 min at 42°C followed by 5 min at 95°C. Then 0.7 m L
(2 U) RNase was added and further incubated for 
20 min at 37°C.
Polymerase chain reaction amplification
Aliquots (1 m L) of reverse transcribed mixture were made
up to 50 m L with reverse transcriptase (RT) buffer contain-
ing 12.5 pmol/m L specific primers and 1 U Taq DNA
polymerase. The b -actin and VIP receptor 1 (R1) primers
used were exactly similar as those reported by Eura et al.
and Park et al., respectively.22,23 The samples were over-
laid with mineral oil and polymerase chain reaction (PCR)
consisted of 1 min of denaturation at 94°C, 2 min of
annealing at 60°C and 3 min of extension at 72°C for 
40 cycles. The PCR products were analyzed on an ethi-
dium bromide-stained 1.5% agarose gel.
Statistical analysis
Results were expressed as the mean ± SEM. Statistical
significance was analyzed by paired Student’s t-test. 
P < 0.05 was considered statistically significant. All
experiments were performed in duplicate.
RESULTS
Vasoactive intestinal peptide-induced
eosinophil chemotaxis and EDN release
At a wide range of doses, VIP elicited eosinophil locomo-
tion and EDN release as can be seen in Fig. 1a,b. These
effects were comparable with those induced by PAF 
(Fig. 1c,d). The EDN release showed a time-dependent
mode and was not due to cytotoxicity, as judged by trypan
blue dye exclusion, which was performed after each de-
granulation period to check cell viability (data not shown).
A checkerboard assay was performed to identify the
nature of eosinophil locomotion in response to VIP.
Whenever cells migrate in response to a concentration
gradients of chemotactic molecules it is termed chemo-
taxis, whereas chemokinesis represent random migration
without the requirement of a concentration gradient.
Figure 2 shows that VIP activity was mainly chemotactic
and to a lesser degree chemokinetic at lower concentra-
tions; however, higher concentrations (10–5 mol/L and
above) demonstrated chemokinetic activity.
Priming effect of rhIL-5
Figure 3 demonstrates the priming effect of 1 ng/mL 
rhIL-5 on eosinophil chemotaxis and EDN release induced
by VIP. Recombinant human IL-5 at the above concentra-
tion did not possess any chemotactic or secretagogue
activity against eosinophil (data not shown); however,
when eosinophils were incubated first with rhIL-5, the cells
showed significant sensitivity against VIP to chemotaxis
and degranulation rather than chemokinetic activity.
Role of free intracellular calcium as a 
second messenger in VIP-induced eosinophil
chemotaxis and EDN release
Figure 4 illustrates the eosinophilotactic and secre-
tagogue activities of VIP against Ca2+-depleted cells. The
quantity of 10–6 mol/L VIP was chosen because it is the
common dose to induce significantly both functions.
Contrary to EDN release, which was almost completely
blocked, eosinophil chemotaxis was not affected under
depletion conditions.
Effect of staurosporine on VIP-induced
eosinophil chemotaxis and degranulation
Pre-exposure of eosinophils to 100 nmol/L staurosporine
prior to VIP induction of eosinophil chemotaxis or
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degranulation resulted in a dose-dependent inhibition 
of EDN release, but did not affect cell migration
(Table 1).
Effect of herbimycin A and pervanadate on
VIP-induced eosinophil chemotaxis
Recently, several reports assigned a role for tyrosine
kinases in leukocyte migration, therefore we next studied
their role on VIP-induced eosinophil chemotaxis using
herbimycin A, the potent tyrosine kinase inhibitor.24,25
Cells were incubated with various doses of the inhibitor
for 1 h, washed and resuspended in the culture medium
and then their chemotactic responses were tested against
VIP in the same way as described in Methods. As shown in
Fig. 5a, pretreatment of eosinophils with herbimycin A
resulted in a dose-dependent potentiation of VIP-induced
eosinophilotactic response.
To further gain insight into the role of tyrosine phos-
phorylation in VIP-induced chemotaxis, eosinophils were
22 A EL-SHAZLY ET AL.
Fig. 1 Comparison of the effects of vasoactive intestinal peptide (VIP) on human eosinophil (a) degranulation and (b) migration. Data
are the mean ± SEM, obtained from 5–8 different experiments. P < 0.05 for (a) 10–4 – 10–7 mol/L and (b) 10–4 – 10–10 mol/L. Similar
dose–response curves were observed in all experiments of chemotaxis. A comparative study on platelet activator factor (PAF) activities is
also shown (c,d). EDN, eosinophil-derived neurotoxin; h.p.f., High power field.
Fig. 2 Checkerboard analysis of vasoactive intestinal peptide
(VIP) on normal human eosinophils. Values represent the mean
number of migrated cells in duplicate filters.
treated with pervanadate, the tyrosine phosphatase
inhibitor.26 Pervanadate treatment resulted in a dose-
dependent inhibition of VIP-induced chemotaxis, as
illustrated in Fig. 5b. As a control, a comparative study
on PAF was also performed; however, neither herbimycin
A nor pervanadate modulated PAF eosinophilotactic
activity (data not shown).
Effect of VIP receptor antagonist on VIP-
induced chemotaxis and EDN release
To test whether VIP interaction with human eosinophils is
receptor mediated, eosinophils were pretreated with
various concentrations of VIP receptor antagonist, [4 Cl-
D-Phe6-Leu17] VIP,27 for 30 min before induction of
chemotaxis and degranulation by VIP. None of the doses
tested, from 10–5 to 10–7 mol/L, modified the activation
of the cells by the corresponding agonist (Fig. 6).
Effect of pertussis toxin on VIP-induced
eosinophil chemotaxis
Pertussis toxin (PTX) catalyzes ADP-ribophosphorylation 
of Gi proteins. To examine the role of Gi proteins in 
VIP-induced eosinophil chemotaxis, eosinophils were
pre-incubated with various concentrations of PTX,
which per se did not affect VIP-induced chemotaxis
(Table 2).
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Fig. 3 Priming effect of 1 ng/mL recombinant human interleukin (rhIL)-5 on 10–6 mol/L vasoactive intestinal peptide (VIP)-induced
eosinophil chemotaxis (a) and degranulation (b). Eosinophils were incubated with the rhIL–5 for 30 min at 37°C, followed by
washing of the cells and resuspension in the culture medium. Eosinophil chemotaxis and degranulation against VIP were then tested,
n = 6. *P < 0.01. Similar results were obtained with 10–7 mol/L VIP. (j), No priming; ( ), priming. EDN, eosinophil-derived 
neurotoxin; h.p.f., high power field.
Fig. 4 Comparison of the eosinophilotactic and secreta-
gogue activities of 10–6 mol/L vasoactive intestinal peptide
(VIP) on Ca2+-depleted eosinophils ( ) versus non-depleted
(j). The results represent the mean ± SEM of 9–12 different
experiments. *P < 0.001. h.p.f., High power field.
Table 1 Effect of staurosporine on 10–6 mol/L VIP-induced
eosinophil chemotaxis and degranulation
Concentration of 
staurosporine Eosinophils/5 h.p.f. EDN (ng)
0 (Buffer) 194.5 ± 14.5 50.0 ± 0.8
100 nmol/L 180.0 ± 8.3 33.0 ± 1.7*
Freshly purified eosinophils were pre-exposed to 100 nmol/L stau-
rosporine for 15 min at 37°C. Results are the mean ± SEM of four
different experiments. VIP, vasoactive intestinal peptide; h.p.f., high
power field; EDN, eosinophil-derived neurotoxin. *P < 0.01.
Expression of VIP-R1 by human eosinophils
and lymphocytes
The amplification products of VIP-R1 were identical to the
predicted size for the mRNA template of 534 b.p. The RT-
PCR products from lymphocytes, but not eosinophils,
expressed signals for VIP-R1 (Fig. 7).
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Fig. 5 Effects of herbimycin A (a) and pervanadate (b) on 10–6 mol/L vasoactive intestinal peptide (VIP)-induced eosinophil
chemotaxis. *P < 0.05 compared with control cells that were pre-incubated with buffer for the same duration. Data are the
mean ± SEM, n = 10. Similar results were obtained with 10–9 mol/L VIP. h.p.f., High power field.
Fig. 6 Effects of vasoactive intestinal peptide (VIP) receptor
antagonist on 10–6 mol/L VIP-induced eosinophil chemotaxis
and degranulation. Cells were pre-incubated with – log 7 ( ),
– log 6 ( ) or – log 5 mol/L (h) receptor antagonist or buffer 
(j; control) for 30 min at 37°C, before adding the correspond-
ing agonist. Results represent the mean ± SEM of six inde-
pendent experiments. Values did not differ significantly from
control cells that were pre-incubated with buffer for the same
duration. Similar results were obtained with 10–9 mol/L VIP.
h.p.f., High power field.
Table 2 Effect of PTX on 10–6 mol/L VIP-induced eosinophil
chemotaxis
Concentration of PTX Eosinophils/5 h.p.f.
0 (Buffer) 194.5 ± 14.5
10 ng/mL 170.0 ± 5.8
100 ng/mL 182.0 ± 10.2
1000 ng/mL 164.0 ± 16.1
Freshly purified eosinophils were incubated for 2 h at 37°C with
various concentrations of pertussis toxin (PTX), followed by washing of
the cells and resuspension in the culture medium. Results are the mean
± SEM of four different experiments. VIP, vasoactive intestinal peptide,
h.p.f., high power field.
Fig. 7 Expression of VIP-R1 in human eosinophils and lym-
phocytes. VIP-R1 was expressed in lymphocytes but not in
eosinophils. Reverse transcriptase polymerase chain reaction
(RT-PCR) was performed on mRNA isolated from each cell type.
The RT-PCR products were electrophoresed in 1.5% agarose
gel and stained with ethidium bromide. M, marker; 1,
eosinophils (b -actin); 2, lymphocytes (b -actin); 3, eosinophils
(VIP-R1); 4, lymphocytes (VIP-R1).
DISCUSSION
It seems certain that VIP induces eosinophil functional
responses from the data presented in Fig. 1, but the
dose–response curves are different from those induced by
PAF, in which a specific cell-surface receptor has been
identified. Although VIP modulates lymphocyte functions
through specific lymphocyte receptors, which are typically
seven transmembrane-coupled receptors, the VIP dose–
response of eosinophils is in favor of non-specific binding
activation. This is supported by: (i) lack of modulation 
of VIP-induced chemotaxis and degranulation by VIP
receptor antagonist (4 Cl-D-Phe6-Leu17) VIP; (ii) lack of
blocking activity of PTX in VIP-induced eosinophil chemo-
taxis; and (iii) lack of VIP-R1 expression by human
eosinophils when compared to human lymphocytes. It 
is possible that VIP non-specific binding to human
eosinophils may be due to either a non-specific charge-
related binding or a lipophilic property. It is of note 
that other peptides, such as melittin and substance P,
have been suggested to activate guinea-pig eosinophils
through non-specific peptide–membrane phospholipid
interaction; moreover, the MBP stimulates several cell
types through negatively charged phospholipid binding
sites.28 Nonetheless, our failure to detect any signals for
VIP-R1 mRNA in the gels does not solely exclude the pos-
sibility of expression of very low non-detectable amounts
in the gel. In fact, only a few hundred protein molecules
of G-protein-linked receptors are sufficient to mediate
functional responses. In addition, the possibility of the
existence of other receptors should be considered. The
exact binding mechanism of VIP with human eosinophils
remains of interest and requires further investigations.
Staurosporine and Ca2+ chelation did not modify VIP
eosinophilotactic activity, which accordingly can exclude
involvement of other pathways in VIP-induced chemo-
taxis, such as phospholipase A and phospholipase D,
which are Ca2+ dependent.29,30 However, modulation of
tyrosine kinases and phosphatases by herbimycin A 
and pervanadate augmented and inhibited eosinophil
chemotaxis, respectively. These interesting results suggest
that the non-specific activation of human eosinophils by
VIP seems to have two pathways: (i) a Ca2+-dependent
pathway involving EDN release; and (ii) a Ca2+-indepen-
dent tyrosine kinase and phosphatase pathway involving
chemotaxis.
In vivo, allergic reactions result in the release of several
mediators, many of which work in synergy, a phenome-
non termed priming with respect to the in vitro studies.
Therefore, we next investigated the priming activity of
rhIL-5 and whether it cooperates with VIP in inducing 
significant eosinophil functional responses. Recombinant
human IL-5 at 1 ng/mL did not induce any eosinophil
chemotaxis or degranulation, but prepared the cell for an
exaggerated response to subsequent stimulation with VIP,
demonstrating a novel cytokine–neuropeptide interaction
in inducing eosinophil functional responses. It is possible
that rhIL-5 causes a change in the signal transduction
pathway(s).
In conclusion, our findings suggest that VIP released in
allergic reactions may act as a pro-inflammatory media-
tor, which exacerbates eosinophilic inflammation, rather
than an anti-inflammatory mediator as a result of
increase in cAMP concentration in other inflammatory
cells, and this effect cannot be modulated by a receptor-
specific antagonist.
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